Option Therapeutics Inc. filed a Form S-1 registration statement for an initial public offering on 2026-01-26. It has amended it 1 time. As of its latest filing, on 2026-03-16, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We intend to apply to list our common stock on NYSE American (“NYSE”) under the symbol “OPTN”.From the S-1/A filed 2026-03-16
Shares offered
We are offering 1,818,182 shares of our common stock.From the S-1/A filed 2026-03-16
Price range
We anticipate that the initial public offering price of shares of our common stock will be between $10.00 and $12.00 per share.From the S-1/A filed 2026-03-16
Use of proceeds
We intend to use the net proceeds from this offering for working capital and general corporate purposes that are necessary in order to operate our company, which will include, among other things, the quarterly fee for support services to be provided under the management services agreement between us and BioVie, and all of the remaining net proceeds from this offering to fund the Phase 3 clinical trial of our investigational drug candidate BIV201 (continuous infusion terlipressin).From the S-1/A filed 2026-03-16
Revenue
In the case of an issuer who had annual revenue of less than $100 million during the most recently completed fiscal year for which audit financial statements are available, had a public float as calculated under paragraph (1) or (2) of this definition that was either zero or less than $700 million.From the S-1/A filed 2026-03-16
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-01-26 | Registration statement filed | S-1 |
| 2026-03-16 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for Option Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.